On November 6, 2025, Dogwood Therapeutics, Inc. announced financial results for the third quarter of 2025 and provided a business update. The company has enrolled 100 patients into the ongoing Phase 2b clinical trial of Halneuron for the treatment of Chemotherapy Induced Neuropathic Pain (CINP), with 80 patients having already completed treatment. We continue to expect the results of a prespecified interim analysis for that trial in the fourth quarter of 2025. Last month, Dogwood secured a worldwide, royalty free license to develop SP16 for the treatment of cancer related pain and chemotherapy induced neuropathy symptoms from Serpin Pharma. A Phase 1b study of SP16 in Chemotherapy Induced Peripheral Neuropathy (CIPN) that is fully funded by the National Cancer Institute is scheduled to begin patient enrollment in the first half of 2026.
